Literature DB >> 14971881

Overexpression of cyclooxygenase-2 in non-small cell lung cancer.

D K Petkova1, C Clelland, J Ronan, L Pang, J M Coulson, S Lewis, A J Knox.   

Abstract

Evidence is accumulating to suggest that the inducible isoenzyme of cyclooxygenase (COX)-2 is up-regulated in human cancers and epidemiological studies indicate that COX inhibitors may have a protective effect on the development of lung cancer. We used immunohistochemistry and Western blotting to investigate COX expression in lung tumour specimens and three lung cancer cell lines. Sixty-five archival lung tissue samples, including 46 squamous cell and 6 adenocarcinoma lung resections, and 13 small cell lung cancer (SCLC) biopsies were studied. Dense and intense cytoplasmic COX-2 staining was found in all 52 resections from non-small cell lung cancer (NSCLC). The staining was diffuse and much stronger than adjacent respiratory epithelium. COX-2 staining was relatively weak in the majority of the SCLC samples. The bronchial and bronchiolar epithelium in the surrounding normal lung structures showed uniform COX immunoreactivity with apical concentration of the stain. There was no increase in COX-1 staining in any tumour type. Western blot analysis of the cancer lines revealed significantly higher expression of COX-1 in CORL23 line and COX-2 in two NSCLC cell lines (MOR/P; A549) compared with the expression of COX-1 and COX-2 in cultured normal bronchial epithelial cells. Our findings demonstrated COX-2 overexpression in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971881     DOI: 10.1016/j.rmed.2003.09.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

1.  Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.

Authors:  Hiroki Takahashi; Aihua Li; David W Dawson; Oscar Joe Hines; Howard A Reber; Guido Eibl
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

2.  Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.

Authors:  Shruti Setia; Vivek Vaish; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2012-03-13       Impact factor: 3.396

3.  Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC).

Authors:  Sruthi Sarvepalli; Vineela Parvathaneni; Gautam Chauhan; Snehal K Shukla; Vivek Gupta
Journal:  Pharm Res       Date:  2022-09-15       Impact factor: 4.580

Review 4.  Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.

Authors:  Andrei Laszlo; Dinesh Thotala; Dennis E Hallahan
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

5.  Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

Authors:  Likun Chen; Youjian He; He Huang; Hai Liao; Weidong Wei
Journal:  Med Oncol       Date:  2008-01-03       Impact factor: 3.064

6.  Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.

Authors:  Kaka Renaldi; Marcellus Simadibrata; Nur Rahadiani; Diah Rini Handjari; Andy William; Fira Sinuraya; Dadang Makmun
Journal:  Turk J Gastroenterol       Date:  2021-11       Impact factor: 1.852

7.  Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.

Authors:  Yong Ming Zhu; Nor Saadah M Azahri; Danny C W Yu; Penella J Woll
Journal:  BMC Cancer       Date:  2008-07-31       Impact factor: 4.430

8.  Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies.

Authors:  Ilaria Postiglione; Angela Chiaviello; Giuseppe Palumbo
Journal:  Cancers (Basel)       Date:  2011-06-09       Impact factor: 6.639

9.  In vitro functional characterization of prostaglandin-endoperoxide synthase 2 during chondrocyte hypertrophic differentiation.

Authors:  Na Li; Qian Wang; Ting Zhu; Longwei Qiao; Fei Zhang; Rui Mi; Bo Wang; Lin Chen; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Oncotarget       Date:  2016-06-14

Review 10.  Bioactive C17 and C18 Acetylenic Oxylipins from Terrestrial Plants as Potential Lead Compounds for Anticancer Drug Development.

Authors:  Lars Porskjær Christensen
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.